NCT06124378 is a Phase 2 clinical trial of Tislelizumab in Colonic Neoplasms, sponsored by First Affiliated Hospital of Guangxi Medical University.

Who is sponsoring NCT06124378?

NCT06124378 is sponsored by First Affiliated Hospital of Guangxi Medical University.

What drugs are being tested in NCT06124378?

Interventions in NCT06124378: Tislelizumab, Oxaliplatin, Capecitabine, Colectomy.

What condition does NCT06124378 study?

NCT06124378 studies Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors.

Is NCT06124378 still recruiting?

NCT06124378 is currently active, enrolled. Last updated 24 September 2025.

Last reviewed 2025-09-24 · How we verify

NCT06124378

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

Active, enrolled Phase 2 Last updated 24 September 2025

What this trial tests

Phase 2 trial testing Tislelizumab in Colonic Neoplasms in 60 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

13 November 2023

Primary endpoint
28 February 2025

30 November 2026

Quick facts

Lead sponsor	First Affiliated Hospital of Guangxi Medical University
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	13 November 2023
Primary completion	28 February 2025
Estimated completion	30 November 2026
Sites	1 location across China

Drugs / interventions tested

Tislelizumab (TISLELIZUMAB) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Capecitabine (capecitabine) — full drug profile →
Colectomy

Conditions studied

Colonic Neoplasms — all drugs for Colonic Neoplasms →
Neoadjuvant Therapy — all drugs for Neoadjuvant Therapy →
Immune Checkpoint Inhibitors — all drugs for Immune Checkpoint Inhibitors →

Sponsor

First Affiliated Hospital of Guangxi Medical University

Who can join

Adults 18 to 75, any sex, with Colonic Neoplasms or Neoadjuvant Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to elucidate the effects of neoadjuvant Tislelizumab combined with chemotherapy in locally advanced Microsatellite Stable (MSS) colon cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Combination immunotherapy for colorectal cancer: Clinical applications, rationale, challenges, and future perspectives.
Fei J, Cai C, Wu W, Shen H, et al · · 2026 · PMID 41950929 · DOI 10.1016/j.xcrm.2026.102728

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting

Other recruiting trials for Colonic Neoplasms

Currently open trials in the same condition.

NCT07173985 — Strategies for Optimizing a Mailed FIT Program in Appalachia · NA · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06371898 — Comparison of MORbidity of Submucosal DIssection Resection of Giant cOlon Lesions Versus Surgery: a National Multicenter · active not recruiting
NCT06119867 — CompariSon Between the EuroPeAn and Japanese pathologiCal InvEstigation for Colon Cancer (SPACE) · Phase 3 · recruiting
NCT06041945 — Artificial Intelligence to Implement Cost-saving Strategies for Colonoscopy Screening Based on in Vivo Prediction of Pol · NA · recruiting

Other First Affiliated Hospital of Guangxi Medical University trials

Trials by the same sponsor.

NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
NCT07342322 — A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatial · Phase 2 · not yet recruiting
NCT07338357 — Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML · EARLY_PHASE1 · not yet recruiting
NCT07132008 — Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer · Phase 3 · not yet recruiting
NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06124378 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Guangxi Medical University
Last refreshed: 24 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06124378.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing